PSORIASIS ERUPTIONS LIKE SIDE EFFECTS AFTER THE USE ETANERCEPT-CASE REPORT
Sažetak
The use of tumor necrosis factor antagonists (anti-TNF) has become a usual practice to treat various inflammatory diseases. Although indicated for the treatment of psoriasis, anti-TNF may paradoxically trigger a psoriasiform condition. We present a case of a female patient who, during the use of etanercept for rheumatoid arthritis, developed psoriasis. After histopathological confirmation and consultation dermatologist concluded that psoriasis is a paradoxical effect of anti-TNF inhibitors. Anti TNF inhibitor is replaced with other biological drug- tocilizumab. After the change of the drug has been a complete resolution of psoriasis eruptions.Paradoxical form of psoriasis after use of anti-TNF inhibitor requires a change of the drug with other mechanism of action.
Reference
Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2012: guias de avaliação e tratamento. 2. ed. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2012.
Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012;30:700-6
Puig L, Morales-Múnera CE, López-Ferrer A, Geli C. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriaticarthritis: case report and review. Dermatology. 2012;225:14-7.
Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNFa therapy for inflamatory bowel disease: A systemic literature review based on 222 cases. J Crohns Colitis. 2013;7:517-24.
Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthema. First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1–14.
Nguyen K, Vleugels RA, Velez NF, Merola JF, Qureshi AA. Psoriasiform reactions to anti-tumor necrosis factor α therapy. J Clin Rheumatol. 2013;19:377–381.
Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233–240.
Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2011;67:179–185.
Ko JM, Gottlieb AB, Kerbleski JF. Induction and exarcerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100-8.
Brunasso AM, Laimer M, Massone C. Paradoxical Reactions to Targeted Biological Treatments: A way to treat and trigger? Acta Derm Venereol. 2010;90:183-5.
Fernandes IC, Torres T, Sanches M, Velho G, Lago P, Selores M. Psoriase induzida por infliximabe. Acta Med Port. 2011;24:709-13.
Denadai R1, Teixeira FV, Saad-Hossne R. The onset of psoriasis during the treatment of inflammatory bowel diseases whit infliximab: should biological therapy be suspended? Arq Gastroenterol. 2012;49:172-6.
Navarro R, Daudén E. Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti factor de necrosis tumoral. Manejo Clinico. Actas Dermo-Sifiliográficas. 2014;105:752-61
Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologic Spectrum of Psoriasiform Skin Reactions Associated With Tumor Necrosis Factor-a Inhibitor Therapy. A Study of 16 Biopsies. Am J Dermatopathol. 2010;32:568-73